351 related articles for article (PubMed ID: 33180377)
1. Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition.
Daifu T; Mikami M; Hiramatsu H; Iwai A; Umeda K; Noura M; Kubota H; Masuda T; Furuichi K; Takasaki S; Noguchi Y; Morita K; Bando T; Hirata M; Kataoka TR; Nakahata T; Kuwahara Y; Iehara T; Hosoi H; Takita J; Sugiyama H; Adachi S; Kamikubo Y
Pediatr Blood Cancer; 2021 Feb; 68(2):e28789. PubMed ID: 33180377
[TBL] [Abstract][Full Text] [Related]
2. RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
Mikami M; Masuda T; Kanatani T; Noura M; Umeda K; Hiramatsu H; Kubota H; Daifu T; Iwai A; Hattori EY; Furuichi K; Takasaki S; Tanaka S; Matsui Y; Matsuo H; Hirata M; Kataoka TR; Nakahata T; Kuwahara Y; Iehara T; Hosoi H; Imai Y; Takita J; Sugiyama H; Adachi S; Kamikubo Y
Mol Cells; 2022 Dec; 45(12):886-895. PubMed ID: 36572559
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil-conjugated PI-polyamides (Chb-M'), a transcription inhibitor of RUNX family, has an anti-tumor activity against SHH-type medulloblastoma with p53 mutation.
Matsui Y; Mineharu Y; Noguchi Y; Hattori EY; Kubota H; Hirata M; Miyamoto S; Sugiyama H; Arakawa Y; Kamikubo Y
Biochem Biophys Res Commun; 2022 Sep; 620():150-157. PubMed ID: 35792512
[TBL] [Abstract][Full Text] [Related]
4. Genetic regulation of the RUNX transcription factor family has antitumor effects.
Morita K; Suzuki K; Maeda S; Matsuo A; Mitsuda Y; Tokushige C; Kashiwazaki G; Taniguchi J; Maeda R; Noura M; Hirata M; Kataoka T; Yano A; Yamada Y; Kiyose H; Tokumasu M; Matsuo H; Tanaka S; Okuno Y; Muto M; Naka K; Ito K; Kitamura T; Kaneda Y; Liu PP; Bando T; Adachi S; Sugiyama H; Kamikubo Y
J Clin Invest; 2017 Jun; 127(7):2815-2828. PubMed ID: 28530640
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
6. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
Shibui Y; Kohashi K; Tamaki A; Kinoshita I; Yamada Y; Yamamoto H; Taguchi T; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1499-1518. PubMed ID: 33221995
[TBL] [Abstract][Full Text] [Related]
7. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
8. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
9. CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.
Nodomi S; Umeda K; Saida S; Kinehara T; Hamabata T; Daifu T; Kato I; Hiramatsu H; Watanabe KI; Kuwahara Y; Iehara T; Adachi S; Konishi E; Nakahata T; Hosoi H; Heike T
Oncogene; 2016 Oct; 35(40):5317-5327. PubMed ID: 27041577
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic targets for the treatment of malignant rhabdoid tumors.
Nemes K; Frühwald MC
Expert Opin Ther Targets; 2018 Apr; 22(4):365-379. PubMed ID: 29528755
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors.
Moreno N; Kerl K
Anticancer Res; 2016 Aug; 36(8):3883-7. PubMed ID: 27466490
[TBL] [Abstract][Full Text] [Related]
12. Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.
Calandrini C; van Hooff SR; Paassen I; Ayyildiz D; Derakhshan S; Dolman MEM; Langenberg KPS; van de Ven M; de Heus C; Liv N; Kool M; de Krijger RR; Tytgat GAM; van den Heuvel-Eibrink MM; Molenaar JJ; Drost J
Cell Rep; 2021 Aug; 36(8):109568. PubMed ID: 34433038
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.
Kuwahara Y; Hosoi H; Osone S; Kita M; Iehara T; Kuroda H; Sugimoto T
Clin Cancer Res; 2004 Sep; 10(17):5940-8. PubMed ID: 15355927
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1.
Kerl K; Moreno N; Holsten T; Ahlfeld J; Mertins J; Hotfilder M; Kool M; Bartelheim K; Schleicher S; Handgretinger R; Schüller U; Meisterernst M; Frühwald MC
Int J Cancer; 2014 Aug; 135(4):989-95. PubMed ID: 24420698
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
[TBL] [Abstract][Full Text] [Related]
17. Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient.
Kuwahara Y; Iehara T; Ichise E; Katsumi Y; Ouchi K; Tsuchiya K; Miyachi M; Konishi E; Sasajima H; Nakamura S; Fumino S; Tajiri T; Johann PD; FrÜhwald MC; Yoshida T; Okuda T; Hosoi H
Anticancer Res; 2020 Nov; 40(11):6159-6170. PubMed ID: 33109553
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
19. Malignant rhabdoid tumor of the liver presented with initial tumor rupture.
Kachanov D; Teleshova M; Kim E; Dobrenkov K; Moiseenko R; Usychkina A; Filin A; Semenkov A; Mitrofanova A; Konovalov D; Shamanskaya T; Novichkova G; Varfolomeeva S
Cancer Genet; 2014 Sep; 207(9):412-4. PubMed ID: 24894493
[TBL] [Abstract][Full Text] [Related]
20. Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.
Schanda J; Lee CW; Wohlan K; Müller-Kuller U; Kunkel H; Coco IQ; Stein S; Metz A; Koch J; Lausen J; Platzbecker U; Medyouf H; Gohlke H; Heuser M; Eder M; Grez M; Scherr M; Wichmann C
Haematologica; 2017 May; 102(5):e170-e174. PubMed ID: 28154087
[No Abstract] [Full Text] [Related]
[Next] [New Search]
